Loading
TPST-4003 is a treatment from Tempest Therapeutics meant to turn a patient's T cells into cancer-hunting CAR-T cells inside the body, aimed at two markers on B cells and plasma cells.
TPST-4003 is Tempest Therapeutics' lead programme, a dual CD19 and BCMA in vivo CAR-T candidate that Tempest is developing for indications in immunology and oncology. The August 2026 registration statement does not state its stage.
1.TPST-4003 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TPST-4003" OR ABSTRACT:"TPST-4003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TPST-4003, not a curated reading list.
Shares Tempest Therapeutics, BCMA, CD19 and the tag pipeline.
Shares In vivo CAR-T and the tag pipeline.
Shares BCMA and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares BCMA and the tag pipeline.
Shares BCMA and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/